U.S. Markets closed

ThromboGenics NV (THR.BR)

Brussels - Brussels Delayed Price. Currency in EUR
Add to watchlist
3.108-0.014 (-0.448%)
At close: 5:35PM CEST
Full screen
Previous Close3.122
Bid2.960 x 10000
Ask3.010 x 500000
Day's Range3.106 - 3.129
52 Week Range2.500 - 3.879
Avg. Volume34,373
Market Cap112.18M
PE Ratio (TTM)-1.86
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters2 years ago

    Thrombogenics swings to net loss as U.S. sales stall

    Belgian biotech group ThromboGenics made a net loss last year as it struggled to build up U.S. business for its main eye drug Jetrea, the company said on Thursday. ThromboGenics said it treated 3,200 U.S. patients with the drug that treats vitreomacular adhesion, which can lead to blindness, against 7,000 patients in 2013. For 2015 ThromboGenics said it expects sales to rise but remain well below 2013 levels, targeting the sale of 3,500 to 4,000 vials of Jetrea. ThromboGenics made a net loss of 51.1 million euros ($54.18 million) last year, against a net profit of 26.4 million euros in 2013, which included a 90 million euro gain from a partnership agreement for sales in Europe.

  • We're sorry this is all we were able to find about this topic.